Time for Action: Investing in Health Canada
Recent data reveals a troubling trend: Health Canada is taking longer to assess generic and biosimilar drug submissions, delaying the arrival of cost-saving prescription medications on the market, and increasing costs for Canadian taxpayers and patients.
As the federal government prepares to unveil its budget on November 4, it is vital that it address these delays through strategic investments in Health Canada’s resources and staffing.
- The number and complexity of drug submissions received by Health Canada have been increasing for many years.
- Resources for its drug review programs have remained largely static and chronically underfunded.
Regulators in other countries have seen similar submission trends and made the strategic hiring investments needed to meet increased demands and maintain predictable business operations.
The issue is pressing.
Author's summary: Canada needs to invest in Health Canada to speed up drug assessments.
More News
- Rising delinquencies test resilience of Canada’s mid-size lenders - CMT News
- Chevron Thailand and Digitas turn lubricant production into immersive roadside experience
- ZoomInfo Shares Face Reality Check Amid Impressive Rally () | aktiencheck.de
- Plans submitted for eight-tower masterplanned community in Sydney
- Plans submitted for 54-storey residential tower in Canary Wharf
- Rethinking megaprojects: Will SF meet its quota of building 82,000 new housing units in 5 years?
- AZZ Shares: A Market Divided on Valuation Prospects () | aktiencheck.de
- How businesses can implement Zero Waste practices